NCT02055729

Brief Summary

The main objective of this study is to characterize the evolution (over a period of 28 days) of superficial and deep bacterial skin flora in patients with stage 3 or 4 sacral pressure ulcers (bedsores). Changes in terms of pathogenic, potentially pathogenic and non-pathogenic bacterial species at the intra-individual and population levels.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2015

Typical duration for all trials

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 4, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 5, 2014

Completed
1.3 years until next milestone

Study Start

First participant enrolled

May 11, 2015

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 21, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 21, 2017

Completed
Last Updated

January 30, 2020

Status Verified

January 1, 2020

Enrollment Period

2.4 years

First QC Date

February 4, 2014

Last Update Submit

January 29, 2020

Conditions

Keywords

bedsorebacteriacolonizationecology

Outcome Measures

Primary Outcomes (4)

  • List of pathogenic, potentially pathogenic and commensal bacterial species in superficial and deep bedsore samples

    At the individual level

    Baseline (day 0)

  • List of pathogenic, potentially pathogenic and commensal bacterial species in superficial and deep bedsore samples

    At the individual level

    Day 28

  • Percentage of pathogenic, potentially pathogenic, and commensal bacterial species in superficial and deep bedsore samples

    Calculated over the entire study population

    baseline (day 0)

  • Percentage of pathogenic, potentially pathogenic, and commensal bacterial species in superficial and deep bedsore samples

    Calculated over the entire study population

    Day 28

Secondary Outcomes (6)

  • Classification of bacteria present according to respiratory type, gram negative/positive, shape, and resistance phenotypes.

    baseline (Day 0)

  • Classification of bacteria present according to respiratory type, gram negative/positive, shape, and resistance phenotypes.

    Day 28

  • List of pathogenic, potentially pathogenic and commensal bacterial species in stool samples

    baseline (day 0)

  • List of pathogenic, potentially pathogenic and commensal bacterial species in stool samples

    Day 28

  • List of pathogenic, potentially pathogenic and commensal bacterial species in urine samples

    baseline (day 0)

  • +1 more secondary outcomes

Study Arms (1)

The study population

The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur. For a description of the study population, see the inclusion/exclusion criteria. Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample

Biological: 3mm tissue punch biopsyBiological: Superficial bedsore sampleBiological: Stool sampleBiological: Urine sample

Interventions

Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).

The study population

Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 \& 28)

The study population
Stool sampleBIOLOGICAL

Stool samples will be collected on days 0 and 28.

The study population
Urine sampleBIOLOGICAL

Urine samples will be collected on days 0 and 28.

The study population

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population consists of patients hospitalized in the Propara neurological rehabilitation (Montpellier, France) having at least one stage 3 or 4 bedsore in the pelvic region.

You may qualify if:

  • The patient was correctly informed about study implementation, its objectives, constraints and patient rights
  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is available for 28 days of follow-up
  • The patient has one or more pelvic pressure ulcers (bedsores)(stage 3 or 4 only). Note: Patients with bedsores of varying stage will be included for the wound corresponding to the highest stage. If the patient has multiple bedsores of the same stage, the deepest wound will be selected.
  • The patient requires a modern wound dressings (i.e. not tulle or gauze) without added bactericidal or antibiotic elements
  • The patient is hospitalized ant the Propara neurological rehabilitation center (Montpellier, France)
  • The patient has not received antibiotics in the last 14 days.

You may not qualify if:

  • The patient is participating in another study, or has participated in another study in the last 3 months
  • The patient is under judicial protection, under tutorship or curatorship
  • The patient refuses to sign the consent
  • It is impossible to correctly inform the patient
  • The patient is pregnant, parturient, or breastfeeding
  • The patient is already included in the present study
  • The patient has sacral pressure ulcers of only stages 1 or 2, or does not have a sacral pressure ulcer
  • Patient under curative anticoagulation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Centre Mutualiste Neurologique Propara

Montpellier, 34090, France

Location

Laboratoire d'Etude et de Recherche en Environnement et Santé, Unité Biodiagnostic, UNIMES

Nîmes, 30000, France

Location

CHRU de Nîmes - Hôpital Universitaire Carémeau

Nîmes, 30029, France

Location

Unité U1047 "Bacterial virulence and infectious diseases", UFR de Médecine

Nîmes, 30908, France

Location

Related Publications (1)

  • Fayolle M, Morsli M, Gelis A, Chateauraynaud M, Yahiaoui-Martinez A, Sotto A, Lavigne JP, Dunyach-Remy C. The Persistence of Staphylococcus aureus in Pressure Ulcers: A Colonising Role. Genes (Basel). 2021 Nov 25;12(12):1883. doi: 10.3390/genes12121883.

Biospecimen

Retention: SAMPLES WITH DNA

Bedsore superficial (swabbing) and deep (punch biopsies) samples are retained; stool and urine samples are retained. DNA extraction is aimed at describing microbial communities.

MeSH Terms

Conditions

Pressure Ulcer

Condition Hierarchy (Ancestors)

Skin UlcerSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Catherine Dunyach-Remy, PhD

    Centre Hospitalier Universitaire de Nîmes

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 4, 2014

First Posted

February 5, 2014

Study Start

May 11, 2015

Primary Completion

September 21, 2017

Study Completion

September 21, 2017

Last Updated

January 30, 2020

Record last verified: 2020-01

Locations